FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3155135364> ?p ?o ?g. }

• W3155135364 endingPage "e220" @default.
• W3155135364 startingPage "e220" @default.
• W3155135364 abstract "Objective: Cilnidipine (Cil) is an L- and N-type calcium channel blocker that inhibits the release of norepinephrine (NE) from the sympathetic nerve endings. It has inhibitory effects on SNA and the renin-angiotensin-aldosterone system (RAAS), as well as its strong renal and vascular protective effects. (Pro)renin receptor [(P)RR] activates the tissue RAAS and contributes to the pathogenesis of organ damages. The soluble form of (P)RR [s(P)RR] is produced via cleavage of (P)RR, and its blood concentration is a biomarker of organ damage. The present study investigated the effects of Cil on serum s(P)RR concentration, as well as the relationships between the serum s(P)RR concentration and changes in NE and aldosterone (ALDO) levels. Design and method: Patients with essential hypertension were randomly assigned to 2 groups: the Cil treatment (C) group (n = 19) and the amlodipine treatment (A) group (18). Changes in various parameters (urinary, biochemistry, and endocrine data and cardio-ankle vascular index (CAVI), an index of arterial stiffness, during the 6 months-treatment period were compared. Results: In both groups, there was a significant decrease in blood pressure by the treatments, while there was no difference in changes in blood pressure between the two groups. In the C group, urinary albumin excretion and CAVI decreased significantly. There were no changes in s(P)RR levels in both groups. Serum NE levels (rate of decline: 13.6 ± 33.3%) and ALDO levels (18.4 ± 33.6%) significantly decreased in the C group. In the C group, while the decline rate of NE was significantly greater in the low s(P)RR group (24.6 ± 31.4%, n = 9) than in the high s(P)RR group (1.2 ± 33.0%, n = 10), changes in ALDO was not significantly different between the groups. Conclusions: The present study reconfirmed that Cil reduces NE and ALDO levels, and has renal and vascular protective effects. Although changes in serum s(P)RR concentration by Cil were not demonstrated, there was an association between the serum s(P)RR levels and the rate of decline of NE, suggesting involvement of (P)RR expression in the regulation of SNA. Future studies are needed to determine the underlying mechanism of this involvement." @default.
• W3155135364 created "2021-04-26" @default.
• W3155135364 creator A5025921038 @default.
• W3155135364 creator A5035902259 @default.
• W3155135364 creator A5052899951 @default.
• W3155135364 date "2021-04-01" @default.
• W3155135364 modified "2023-09-25" @default.
• W3155135364 title "EFFECT OF L- AND N-TYPE CALCIUM CHANNEL BLOCKER CILNIDIPINE ON SERUM SOLUBLE (PRO)RENIN RECEPTOR CONCENTRATION" @default.
• W3155135364 doi "https://doi.org/10.1097/01.hjh.0000746920.33532.71" @default.
• W3155135364 hasPublicationYear "2021" @default.
• W3155135364 type Work @default.
• W3155135364 sameAs 3155135364 @default.
• W3155135364 citedByCount "0" @default.
• W3155135364 crossrefType "journal-article" @default.
• W3155135364 hasAuthorship W3155135364A5025921038 @default.
• W3155135364 hasAuthorship W3155135364A5035902259 @default.
• W3155135364 hasAuthorship W3155135364A5052899951 @default.
• W3155135364 hasBestOaLocation W31551353641 @default.
• W3155135364 hasConcept C126322002 @default.
• W3155135364 hasConcept C134018914 @default.
• W3155135364 hasConcept C198710026 @default.
• W3155135364 hasConcept C2778525890 @default.
• W3155135364 hasConcept C2779646130 @default.
• W3155135364 hasConcept C2780356492 @default.
• W3155135364 hasConcept C71924100 @default.
• W3155135364 hasConcept C84393581 @default.
• W3155135364 hasConceptScore W3155135364C126322002 @default.
• W3155135364 hasConceptScore W3155135364C134018914 @default.
• W3155135364 hasConceptScore W3155135364C198710026 @default.
• W3155135364 hasConceptScore W3155135364C2778525890 @default.
• W3155135364 hasConceptScore W3155135364C2779646130 @default.
• W3155135364 hasConceptScore W3155135364C2780356492 @default.
• W3155135364 hasConceptScore W3155135364C71924100 @default.
• W3155135364 hasConceptScore W3155135364C84393581 @default.
• W3155135364 hasIssue "Supplement 1" @default.
• W3155135364 hasLocation W31551353641 @default.
• W3155135364 hasLocation W31551353642 @default.
• W3155135364 hasOpenAccess W3155135364 @default.
• W3155135364 hasPrimaryLocation W31551353641 @default.
• W3155135364 hasRelatedWork W1967336868 @default.
• W3155135364 hasRelatedWork W1967659878 @default.
• W3155135364 hasRelatedWork W1976450327 @default.
• W3155135364 hasRelatedWork W1992220075 @default.
• W3155135364 hasRelatedWork W2006202112 @default.
• W3155135364 hasRelatedWork W2024736606 @default.
• W3155135364 hasRelatedWork W2042263844 @default.
• W3155135364 hasRelatedWork W2047608102 @default.
• W3155135364 hasRelatedWork W2077998387 @default.
• W3155135364 hasRelatedWork W2126797993 @default.
• W3155135364 hasVolume "39" @default.
• W3155135364 isParatext "false" @default.
• W3155135364 isRetracted "false" @default.
• W3155135364 magId "3155135364" @default.
• W3155135364 workType "article" @default.